Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Radiother Oncol. 2021 Apr 8;160:32–39. doi: 10.1016/j.radonc.2021.03.036

Fig. 2.

Fig. 2.

The numbers of patients with XQ scores at 0–6 months after treatment and at the indicated subsequent times. (A) Four hundred thirteen patients had XQ scores at 0–6 months, but only 142, 107, 145, 148, and 181 of those patients also had XQ scores at 6–9, 9–12, 12–18, 18–24, and 24–36 months, respectively. (B) The proportions of the 142 patients with moderate-severe xerostomia (XQs ≥50) in both treatment groups who had XQ scores at both 0–6 and 6–9 months. (C-F) The proportions of the (C) 107 patients with XQ scores at 0–6 and 9–12 months, (D) 145 patients with XQ scores at 0–6 and 12–18 months, (E) 148 patients with XQ scores at 0–6 and 18–24 months, and (F) 181 patients with XQ scores at 0–6 and 24–36 months in the IMRT and IMPT groups. Fewer patients in the IMPT group than in the IMRT group had moderate-severe xerostomia (XQs ≥50) at 18–24 months (p = 0.035) and 24–36 months (p = 0.034) after treatment.